In a deal expected to disrupt the Canadian market, Resolve Digital Health Inc. (“Resolve”), a Canadian developer of intelligent medical cannabis delivery devices, has concluded an exclusive agreement with Aphria Inc. (“Aphria”), one of Canada’s largest licensed producers of medical cannabis.
Under the agreement, Aphria will provide cannabis products to fill Resolve’s proprietary delivery pods and cartridges for sale to the Canadian medical cannabis market.
Vic Neufeld, CEO of Aphria and Chairman of the Board for Liberty Health Sciences Inc. (“Liberty”), said: “Aphria is delighted to partner with Resolve in Canada. This agreement is consistent with both companies’ commitment to leading in the space, and to bringing safe and effective cannabis products as part of a holistic medical cannabis ecosystem for Canadian patients.”
In the US, medical cannabis sales are projected to grow from $4.7 billion in 2016 to $13.3 billion in 2020.
In Canada alone, the patient population using medical cannabis for various indications is growing at a pace of more than 10,000 new patients per month, and reached 201,398 in June 2017,2 a 268 per cent increase from the 75,166 registered at the end of June 2016.
Across a growing number of jurisdictions, medical cannabis is being prescribed to help relieve chemotherapy-induced nausea and vomiting, as well as pain associated with cancer, and the management of chronic pain, arthritis and joint disorders, multiple sclerosis (MS), fibromyalgia and migraines. Partnership with Liberty Health Sciences Inc. in Florida
Nick Waddell – Cantech Letter – October 31, 2017.
Want More Investigative Content?
